review on cardio-hepatic toxic macrolide: Azythromycin
Open Access
- 14 July 2024
- journal article
- review article
- Published by Universidad Tecnica de Manabi in International journal of health sciences
- Vol. 8 (S1) , 854-865
Abstract
Drug-induced cardio-hepatic toxicity is the foremost cause of heart and liver damage, with the use of antimicrobial-agent. Most patients, although recuperate after discontinuing the offending-agent, severe cases may consequence in progressive disease. Azithromycin is a rare cause of idiosyncratic drug-induced cardiac and liver injury. This semi-synthetic macrolide has a substantial potency against both gram-positive and gram-negative organisms due to the presence of a nitrogen atom in its ring. A search was performed in PubMed, Scopus, Google Scholar and Research Gate. Azithromycin divulges a lower number of interactions with proteins, whereas, QTc prolongation with torsades de pointes (Tdp) and polymorphic ventricular tachycardia are communally occurred in cardiovascular system, due to dysregulation of intracellular [Ca++] via the Na+-Ca++ exchanger activity, leading to delayed after depolarizations. In addition azithromycin-induced liver injury was more cholestatic in nature, with an ALT/ALP ratio of <2 ULN, contributing vanishing bile duct syndrome. This review hereafter revealed the adverse effect of azithromycin in relation with cardio – hepatic toxicity.Keywords
This publication has 45 references indexed in Scilit:
- Analyzing the Mechanisms Behind Macrolide Antibiotic-Induced Liver Injury Using Quantitative Systems Toxicology ModelingPharmaceutical Research, 2019
- MITOsym®: A Mechanistic, Mathematical Model of Hepatocellular Respiration and BioenergeticsPharmaceutical Research, 2014
- Interethnic Differences in Pharmacokinetics of AntibacterialsClinical Pharmacokinetics, 2014
- Linking physiology to toxicity using DILIsym®, a mechanistic mathematical model of drug‐induced liver injuryBiopharmaceutics & Drug Disposition, 2013
- Drug-Induced Liver Injury Throughout the Drug Development Life Cycle: Where We Have Been, Where We are Now, and Where We are Headed. Perspectives of a Clinical HepatologistPharmaceutical Medicine, 2013
- A concise review of HPLC, LC‐MS and LC‐MS/MS methods for determination of azithromycin in various biological matricesBiomedical Chromatography, 2013
- In vitro to in vivo extrapolation and species response comparisons for drug-induced liver injury (DILI) using DILIsym™: a mechanistic, mathematical model of DILIJournal of Pharmacokinetics and Pharmacodynamics, 2012
- Azithromycin as a cause of QT-interval prolongation and torsade de pointes in the absence of other known precipitating factorsJournal of Interventional Cardiac Electrophysiology, 2007
- Nucleic Acids (Deoxyribonucleic Acid and Ribonucleic Acid)2007
- Azithromycin—Spectrum of Activity, Pharmacokinetics, and Clinical ApplicationsPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 1992